Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to ...

The first long-term comparison of psilocybin vs an SSRI for MDD suggests the psychedelic was associated with better overall ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) ...

This study aimed to explore the association between major depressive disorder (MDD) and suicide risk in dementia patients.A cohort of 625,218 individuals aged ≥40 years with dementia between 2007 and ...

Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, ...

Researchers found that psilocybin therapy provides long-term relief from depressive symptoms similar to escitalopram while ...

A recent research highlights the potential of psilocybin as a groundbreaking treatment for moderate to severe major ...

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an ...

Here's a look at the best and worst states in each of the four data categories: mental health provider ratio, suicide rate ...

the active compound in 'magic mushrooms,' may offer more effective outcomes for treating moderate to severe major depressive disorder compared to the commonly prescribed antidepressant escitalopram, a ...

SSRI (Selective Serotonin Reuptake Inhibitors) antidepressants like escitalopram improve mood and cognitive functions by ...

Researchers have found that SSRI (selective serotonin reuptake inhibitor) antidepressants have the potential to improve ...